The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes

被引:1017
作者
de Lemos, JA
Morrow, DA
Bentley, JH
Omland, T
Sabatine, MS
McCabe, CH
Hall, C
Cannon, CP
Braunwald, E
机构
[1] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[3] Nottingham Clin Res Grp, Nottingham, England
[4] Univ Oslo, Natl Hosp, Internal Med Res Inst, Oslo, Norway
关键词
D O I
10.1056/NEJMoa011053
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Brain (B-type) natriuretic peptide is a neurohormone synthesized predominantly in ventricular myocardium. Although the circulating level of this neurohormone has been shown to provide independent prognostic information in patients with transmural myocardial infarction, few data are available for patients with acute coronary syndromes in the absence of ST-segment elevation. Methods: We measured B-type natriuretic peptide in plasma specimens obtained a mean (+/-SD) of 40+/-20 hours after the onset of ischemic symptoms in 2525 patients from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction 16 study. Results: The base-line level of B-type natriuretic peptide was correlated with the risk of death, heart failure, and myocardial infarction at 30 days and 10 months. The unadjusted rate of death increased in a stepwise fashion among patients in increasing quartiles of base-line B-type natriuretic peptide levels (P<0.001). This association remained significant in subgroups of patients who had myocardial infarction with ST-segment elevation (P=0.02), patients who had myocardial infarction without ST-segment elevation (P<0.001), and patients who had unstable angina (P<0.001). After adjustment for independent predictors of the long-term risk of death, the odds ratios for death at 10 months in the second, third, and fourth quartiles of B-type natriuretic peptide were 3.8 (95 percent confidence interval, 1.1 to 13.3), 4.0 (95 percent confidence interval, 1.2 to 13.7), and 5.8 (95 percent confidence interval, 1.7 to 19.7). The level of B-type natriuretic peptide was also associated with the risk of new or recurrent myocardial infarction (P=0.01) and new or worsening heart failure (P<0.001) at 10 months. Conclusions: A single measurement of B-type natriuretic peptide, obtained in the first few days after the onset of ischemic symptoms, provides predictive information for use in risk stratification across the spectrum of acute coronary syndromes. Cardiac neurohormonal activation may be a unifying feature among patients at high risk for death after acute coronary syndromes. (N Engl J Med 2001;345:1014-21.) Copyright (C) 2001 Massachusetts Medical Society.
引用
收藏
页码:1014 / 1021
页数:8
相关论文
共 30 条
[1]   Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the thrombolysis in myocardial infarction (TIMI) 11B trial [J].
Antman, EM ;
McCabe, CH ;
Gurfinkel, EP ;
Turpie, AGG ;
Bernink, PJLM ;
Salein, D ;
de Luna, AB ;
Fox, K ;
Lablanche, JM ;
Radley, D ;
Premmereur, J ;
Braunwald, E .
CIRCULATION, 1999, 100 (15) :1593-1601
[2]   RELATIONSHIP BETWEEN PLASMA-LEVEL OF BRAIN NATRIURETIC PEPTIDE AND MYOCARDIAL INFARCT SIZE [J].
ARAKAWA, N ;
NAKAMURA, M ;
AOKI, H ;
HIRAMORI, K .
CARDIOLOGY, 1994, 85 (05) :334-340
[3]   Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction [J].
Arakawa, N ;
Nakamura, M ;
Aoki, H ;
Hiramori, K .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (07) :1656-1661
[4]   Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. [J].
Cannon, CP ;
Weintraub, WS ;
Demopoulos, LA ;
Vicari, R ;
Frey, MJ ;
Lakkis, N ;
Neumann, FJ ;
Robertson, DH ;
DeLucca, PT ;
DiBattiste, PM ;
Gibson, CM ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1879-1887
[5]   Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial [J].
Cannon, CP ;
McCabe, CH ;
Wilcox, RG ;
Langer, A ;
Caspi, A ;
Berink, P ;
Lopez-Sendon, J ;
Toman, J ;
Charlesworth, A ;
Anders, RJ ;
Alexander, JC ;
Skene, A ;
Braunwald, E .
CIRCULATION, 2000, 102 (02) :149-156
[6]   A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study [J].
Cheng, V ;
Kazanagra, R ;
Garcia, A ;
Lenert, L ;
Krishnaswamy, P ;
Gardetto, N ;
Clopton, P ;
Maisel, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :386-391
[7]   Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting [J].
Dao, Q ;
Krishnaswamy, P ;
Kazanegra, R ;
Harrison, A ;
Amirnovin, R ;
Lenert, L ;
Clopton, P ;
Alberto, J ;
Hlavin, P ;
Maisel, AS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :379-385
[8]   Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction [J].
Darbar, D ;
Davidson, NC ;
Gillespie, N ;
Choy, AMJ ;
Lang, CC ;
Shyr, Y ;
McNeill, GP ;
Pringle, TH ;
Struthers, AD .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (03) :284-287
[9]   RAPID VENTRICULAR INDUCTION OF BRAIN NATRIURETIC PEPTIDE GENE-EXPRESSION IN EXPERIMENTAL ACUTE MYOCARDIAL-INFARCTION [J].
HAMA, N ;
ITOH, H ;
SHIRAKAMI, G ;
NAKAGAWA, O ;
SUGA, S ;
OGAWA, Y ;
MASUDA, I ;
NAKANISHI, K ;
YOSHIMASA, T ;
HASHIMOTO, Y ;
YAMAGUCHI, M ;
HORI, R ;
YASUE, H ;
NAKAO, K .
CIRCULATION, 1995, 92 (06) :1558-1564
[10]   Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels [J].
Hamm, CW ;
Heeschen, C ;
Goldmann, B ;
Vahanian, A ;
Adgey, J ;
Miguel, CM ;
Rutsch, W ;
Berger, J ;
Kootstra, J ;
Simoons, ML .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) :1623-1629